Bleomycin hydrolase (BMH) is a cytoplasmic cysteine peptidase that is highly conserved through evolution. Its biological function is hydrolysis of the reactive electrophile homocysteine thiolactone.[8] Another of its activities is metabolic inactivation of the glycopeptide bleomycin (BLM), an essential component of combination chemotherapy regimens for cancer. The protein contains the signature active site residues of the cysteine protease papain superfamily.[7]
^Montoya SE, Ferrell RE, Lazo JS (October 1997). "Genomic structure and genetic mapping of the human neutral cysteine protease bleomycin hydrolase". Cancer Res. 57 (19): 4191–5. PMID9331073.
^ abKoldamova RP, Lefterov I M, DiSabella M T, Almonte C, Watkins S C, Lazo J S (June 1999). "Human bleomycin hydrolase binds ribosomal proteins". Biochemistry. 38 (22). UNITED STATES: 7111–7. doi:10.1021/bi990135l. ISSN0006-2960. PMID10353821.
^Koldamova RP, Lefterov I M, DiSabella M T, Lazo J S (December 1998). "An evolutionarily conserved cysteine protease, human bleomycin hydrolase, binds to the human homologue of ubiquitin-conjugating enzyme 9". Mol. Pharmacol. 54 (6). UNITED STATES: 954–61. doi:10.1124/mol.54.6.954. ISSN0026-895X. PMID9855622. S2CID2272861.
Maruyama K, Sugano S (1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides". Gene. 138 (1–2): 171–4. doi:10.1016/0378-1119(94)90802-8. PMID8125298.
Ferrando AA, Velasco G, Campo E, Lopez-Otin C (1996). "Cloning and expression analysis of human bleomycin hydrolase, a cysteine proteinase involved in chemotherapy resistance". Cancer Res. 56 (8): 1746–50. PMID8620487.
Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, et al. (1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library". Gene. 200 (1–2): 149–56. doi:10.1016/S0378-1119(97)00411-3. PMID9373149.
Koldamova RP, Lefterov IM, Gadjeva VG, Lazo JS (1998). "Essential binding and functional domains of human bleomycin hydrolase". Biochemistry. 37 (8): 2282–90. doi:10.1021/bi9722204. PMID9485374.
Montoya SE, Aston CE, DeKosky ST, et al. (1998). "Bleomycin hydrolase is associated with risk of sporadic Alzheimer's disease". Nat. Genet. 18 (3): 211–2. doi:10.1038/ng0398-211. PMID9500538. S2CID2940414.
Koldamova RP, Lefterov IM, DiSabella MT, Lazo JS (1999). "An evolutionarily conserved cysteine protease, human bleomycin hydrolase, binds to the human homologue of ubiquitin-conjugating enzyme 9". Mol. Pharmacol. 54 (6): 954–61. doi:10.1124/mol.54.6.954. PMID9855622. S2CID2272861.
Takeda A, Nonaka M, Ishikawa A, Higuchi D (1999). "Immunohistochemical localization of the neutral cysteine protease bleomycin hydrolase in human skin". Arch. Dermatol. Res. 291 (4): 238–40. doi:10.1007/s004030050400. PMID10335922. S2CID10799259.
Malherbe P, Faull RL, Richards JG (2000). "Regional and cellular distribution of bleomycin hydrolase mRNA in human brain: comparison between Alzheimer's diseased and control brains". Neurosci. Lett. 281 (1): 37–40. doi:10.1016/S0304-3940(00)00802-8. PMID10686410. S2CID41562274.
Nivet-Antoine V, Coulhon MP, Le Denmat C, et al. (2003). "[Apolipoprotein E and bleomycin hydrolase. Polymorphisms: association with neurodegenerative diseases]". Ann. Biol. Clin. (Paris). 61 (1): 61–7. PMID12604387.